论文部分内容阅读
目的探讨拉米夫定联合干扰素序贯治疗慢性乙型肝炎临床疗效。方法 100例慢性乙型肝炎患者随机分为联合组(拉米夫定联合干扰素)和拉米夫定组,每组各40例。结果 HBVDNA阴转率两组均为100%;HBeAg血清转换率联合组为82%、拉米夫定组为44%;HBeAg阴转率联合组为84%、拉米夫定组为42%;ALT复常率联合组为100%、拉米夫定组为94%。结论拉米夫定联合干扰素的治疗可诱导包括抗-HB,血清学转换的持续应答,能迅速控制病毒血症,降低拉米夫定的耐药性的发生,有效改善患者肝功能,提高临床疗效,值得临床推广。
Objective To investigate the clinical efficacy of lamivudine combined with interferon in the treatment of chronic hepatitis B patients. Methods 100 patients with chronic hepatitis B were randomly divided into combined group (lamivudine combined with interferon) and lamivudine group, 40 cases in each group. Results The negative rate of HBVDNA was 100% in both groups. The HBeAg seroconversion rate was 82% in the combination group and 44% in the lamivudine group. The HBeAg negative conversion rate was 84% in the combination group and 42% in the lamivudine group. ALT normalization rate was 100% in the combination group and 94% in the lamivudine group. Conclusion The combination of lamivudine and interferon can induce a sustained response including anti-HB, seroconversion, viremia can be rapidly controlled, the drug resistance of lamivudine can be decreased, the liver function of patients can be improved, Clinical efficacy, it is worth clinical promotion.